Accele Biopharma

Accele Biopharma, established in 2011 and based in Oklahoma City, is an early-stage venture capital firm that specializes in the healthcare and life sciences sectors. The firm focuses on investing in emerging companies within pharmaceuticals, biotechnology, and oncology, aiming to support innovations that advance medical technology and improve patient outcomes. By targeting early-stage ventures, Accele Biopharma seeks to foster growth and development in critical areas of healthcare, contributing to advancements in life science and technology.

Richard Gammans

President and Chief Operating Officer

Elaine Hamm

Chief Operating Officer

12 past transactions

SigTuple

Seed Round in 2016
SigTuple Technologies Private Limited focusses on developing solutions for the automated analysis of medical images and data to aid diagnosis. It offers a peripheral blood smear analyzer that automates differential counts, as well as provides a screening solution for various parasitic infections (malaria), diseases (anemia), and cancerous cells; radiology solutions; and a screening tool to detect pre-cancerous cells in pap smear slides. The company was founded in 2015 and is based in Bengaluru, India.

Knewton

Series F in 2016
Knewton, Inc. is a developer of an online adaptive learning engine that personalizes education for students by providing tailored recommendations on what to study. The platform also equips teachers with analytics to enhance their support for individual students and offers publishers insights to create more effective digital educational products. Knewton's technology serves a range of subjects, including math, economics, and sciences, and is utilized by educational institutions and companies worldwide. In addition to its flagship product, Knewton offers Alta, an integrated adaptive learning courseware for higher education. Founded in 2008 and headquartered in New York, Knewton has expanded its presence internationally with offices in London, Tokyo, Singapore, and Dubai. The company has been recognized for its innovation in education technology, earning accolades such as being named a “Technology Pioneer” by the World Economic Forum.

Synereca Pharmaceuticals

Venture Round in 2015
Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company operates laboratories in Oklahoma and North Carolina, where it synthesizes compounds aimed at restoring or increasing the potency of antibiotics such as Colistin, polymyxins, carbapenems, aminoglycosides, and fluoroquinolones against gram-negative bacteria. Additionally, Synereca's portfolio includes prototypic RecA inhibitors designed to target a variety of pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other dangerous gram-positive and gram-negative pathogens.

Pamlico Biopharma

Series A in 2015
Pamlico Biopharma, Inc. is engaged in the development of fully-human monoclonal antibody therapeutics aimed at addressing human pathogens, cancer, and autoimmune diseases. Headquartered in Oklahoma City, the company focuses on innovative solutions for severe pneumonia caused by Streptococcus pneumoniae. Its lead program is centered on a monoclonal antibody cocktail designed to combat this infection, along with a companion point-of-care diagnostic targeting three serotypes responsible for over 40% of these cases. Founded on technologies from the Oklahoma Medical Research Foundation and Emory University, Pamlico Biopharma is currently involved in preclinical activities and is expected to advance to clinical trials in the near future.

Synereca Pharmaceuticals

Debt Financing in 2014
Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company operates laboratories in Oklahoma and North Carolina, where it synthesizes compounds aimed at restoring or increasing the potency of antibiotics such as Colistin, polymyxins, carbapenems, aminoglycosides, and fluoroquinolones against gram-negative bacteria. Additionally, Synereca's portfolio includes prototypic RecA inhibitors designed to target a variety of pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other dangerous gram-positive and gram-negative pathogens.

Otologic Pharmaceutics

Series A in 2014
Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders. OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.

Artimi

Series A in 2004
Artimi a fables semiconductor company, engages in the development, marketing, and sale of semiconductors, software, and reference designs for the delivery of high speed wireless connectivity in portable consumer electronics devices. The company offers silicon solutions for high bandwidth wireless connectivity based on ultra wideband technologies. Its products include MAC controllers, wireless USB evaluation kits, wireless USB adaptor reference design kits, hard disk drive reference design kits, and printer reference design kits.

ItemField

Series B in 2004
ItemField is a provider of real-time, bi-directional, XML based data transformation software. ItemField's innovative ContentMaster software suite uses a patented new parsing-by-example technology that - for the first time - allows for the transformation of data via XML, from any data format to any other, with no programming required.

Coremetrics

Series C in 2001
Coremetrics is a provider of digital marketing optimization solutions and web analytics. Its solutions are designed to generate high return on online marketing investments.

Quokka Sports

Post in 2000
Quokka Sports, Inc. provides sports entertainment services for the global digital world. The company operates through two divisions: Qmedia, a media production division; and Qtech, a live content technology solutions division. QMedia's principal activities include the acquisition and control of digital rights; production of live sports and entertainment content; publishing and production of web content such as website development for live events, content production, and website maintenance; and creative sponsorship campaign development and sales. QTech develops and manages the company's proprietary Live_IP technology and services that focus on delivering real-time and near real-time immersive media content for the internet, broadband, interactive and enhanced TV, and wireless platforms. The Live_IP platform consists of two primary components, a near real-time content viewer and a live content publishing system. These tools offer content producers, a browser-based publishing platform for creating, editing, assembling, and laying out media-rich content into overlapping content layers that aid content producers in the complete production of projects.

ROI Direct.com

Venture Round in 2000
Founded in June of 1999, ROI Direct offers e-commerce site development and hosting, e-marketing program design and execution, and online customer care solutions tailored to Their clients’ needs. They provide application services, 24x7 systems management, account support, feature upgrades, and shared use of Their multi-million dollar systems infrastructure for less than Their clients’ typical costs of a single IT employee. By customizing Their re-usable set of advanced applications, They’re also able to deliver these solutions in a fraction of the time of in-house or competing third-party solutions.

New Edge Networks

Series A in 1999
New Edge Networks is a provider specializing in wholesale DSL services and secure multi-site managed data networks. Catering primarily to small and mid-sized markets, the company offers dedicated internet access solutions designed to meet the needs of businesses seeking reliable connectivity. By focusing on these specific market segments, New Edge Networks aims to deliver tailored services that enhance operational efficiency and support the growing demand for data-driven solutions.